Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William White

Hypertension Specialist Farmington, CT Medical Doctor

NPI 1760489546 CMS profile 262107

263 Farmington Ave, Farmington, CT 06030

Open in the dashboard

General payments

$2,138,138

395 records reported · program years 2019–2025

Research payments

$572,367

Paid to them · 93 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,926 paid to institutions, not to them · program year 2019

Through program year 2025, William White of Farmington, CT is reported in the CMS Open Payments database as having received $2,138,138 across 395 general payments and $572,367 in research payments paid to them. Separately, studies naming them as principal investigator received $1,926 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $398,625 58
2025 Research $124,843 12
2024 General $357,302 63
2024 Research $76,359 12
2023 General $226,106 47
2023 Research $50,099 9
2022 General $318,384 59
2022 Research $79,000 19
2021 General $344,374 61
2021 Research $59,388 14
2020 General $194,888 33
2020 Research $141,886 18
2019 General $298,459 74
2019 Research $40,793 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William White
  • Connecticut median
  • Middle half of Connecticut
  • National median

In program year 2025, general payments to William White were reported at $398,625. Among 12,665 Connecticut profiles paid that year, the median was $167 and the middle half received between $54 and $639.

Show as a table
Year William White Connecticut median Middle half National median
2019 $298,459 $163 $50–$671 $163
2020 $194,888 $111 $33–$382 $114
2021 $344,374 $124 $39–$443 $132
2022 $318,384 $138 $45–$535 $149
2023 $226,106 $148 $47–$556 $160
2024 $357,302 $157 $49–$599 $164
2025 $398,625 $167 $54–$639 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ucb SA $354,060 55 payments
  2. Sumitomo Pharma America, Inc. $342,445 26 payments
  3. Alnylam Pharmaceuticals Inc. $229,050 43 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $174,432 43 payments
  5. Jazz Pharmaceuticals Inc. $172,173 46 payments
  6. E.R. Squibb & Sons, L.L.C. $127,563 19 payments
  7. AstraZeneca Pharmaceuticals LP $126,445 30 payments
  8. AstraZeneca UK Limited $116,016 41 payments
  9. RedHill Biopharma Inc. $93,504 6 payments
  10. Retrophin, Inc. $84,500 26 payments
  11. Other $317,950 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,130,586 360 payments
  2. Travel and Lodging $4,111 13 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,441 1 payment
  4. Food and Beverage $1,000 21 payments
Products named General payments · program years 2019–2025
  1. XYWAV $135,887 33 payments
  2. Movantik Opioid Antagonist $93,504 6 payments
  3. SOTYKTU $74,419 11 payments
  4. ONPATTRO $51,941 10 payments
  5. SAPHNELO $50,265 17 payments
  6. Uloric $41,017 19 payments
  7. Bimzelx $39,210 12 payments
  8. NORTHERA $21,990 5 payments
  9. MOVANTIK Neuroscience $18,190 1 payment
  10. Aciphex $16,298 1 payment
  11. Other $76,848 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $299,381 45 payments
  2. E.R. Squibb & Sons, L.L.C. $123,206 14 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $38,386 6 payments
  4. AstraZeneca UK Limited $36,543 8 payments
  5. Novartis Pharmaceuticals Corporation $28,500 3 payments
  6. Mylan Inc. $20,550 4 payments
  7. Amryt Pharma Holdings Ltd $17,950 10 payments
  8. Aegerion Pharmaceuticals, Inc. $4,250 1 payment
  9. Chiesi USA, Inc. $3,600 2 payments

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hypertension Specialist in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record